跳轉至內容
Merck
全部照片(1)

重要文件

Y0000588

文拉法辛

European Pharmacopoeia (EP) Reference Standard

同義詞:

文拉法辛 盐酸盐, (+/-)-1-[2-(二甲基氨基)-1-(4-甲氧基苯基)乙基]环己醇盐酸盐, 盐酸文拉法辛

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C17H27NO2 · HCl
CAS號碼:
分子量::
313.86
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

venlafaxine

製造商/商標名

EDQM

應用

pharmaceutical (small molecule)

形式

neat

SMILES 字串

Cl[H].COc1ccc(cc1)C(CN(C)C)C2(O)CCCCC2

InChI

1S/C17H27NO2.ClH/c1-18(2)13-16(17(19)11-5-4-6-12-17)14-7-9-15(20-3)10-8-14;/h7-10,16,19H,4-6,11-13H2,1-3H3;1H

InChI 密鑰

QYRYFNHXARDNFZ-UHFFFAOYSA-N

基因資訊

尋找類似的產品? 前往 產品比較指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Venlafaxine for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

生化/生理作用

文拉法辛是抗抑郁药。文拉法辛在人中的抗抑郁作用机制与其在中枢神经系统中神经递质活性的增强有关。文拉法辛是神经元 5-羟色胺和去甲肾上腺素再摄取的有效抑制剂,是多巴胺再摄取的弱抑制剂。在体外,文拉法辛对毒蕈碱、组胺能或 α-1 肾上腺素能受体无明显活性。文拉法辛不具有 MAO 抑制剂活性。

包裝

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他說明

Sales restrictions may apply.

象形圖

Environment

危險聲明

防範說明

危險分類

Aquatic Chronic 2

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


從最近期的版本中選擇一個:

分析證明 (COA)

Lot/Batch Number

抱歉,我們目前沒有在線上提供本產品的COA

如果您需要協助,請聯絡 客戶支援

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

M Batista et al.
Clinical toxicology (Philadelphia, Pa.), 51(2), 92-95 (2013-01-11)
Venlafaxine is a bicyclic antidepressant that may be associated with severe cardiotoxicity following large overdose. The purpose of this short case series is to present different patterns of venlafaxine-related cardiotoxicity and to discuss the potential mechanisms. Between January 2010 and
Mara Z Vitolins et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(32), 4092-4098 (2013-10-02)
Hot flashes occur in approximately 80% of androgen-deprived men. Few intervention studies have been conducted to relieve hot flashes in men. Eligible androgen-deprived men were randomly assigned to one of four daily regimens (2 × 2 factorial design) for 12
Aaron S Heller et al.
The American journal of psychiatry, 170(2), 197-206 (2012-12-12)
OBJECTIVE Deficits in positive affect and their neural bases have been associated with major depression. However, whether reductions in positive affect result solely from an overall reduction in nucleus accumbens activity and fronto-striatal connectivity or the additional inability to sustain
Kara N D Polen et al.
Birth defects research. Part A, Clinical and molecular teratology, 97(1), 28-35 (2013-01-03)
Few epidemiologic studies have investigated the use of venlafaxine (Effexor XR capsules, Product Monograph, Wyeth, Montreal, Canada), an antidepressant used to treat major depression and anxiety disorders in adults, during pregnancy. Our objective was to determine whether use of venlafaxine
Yaal Lester et al.
Water research, 47(13), 4349-4356 (2013-06-15)
Wastewater from a pharmaceutical formulation facility (TevaKS, Israel) was treated with a biological activated-sludge system followed by ozonation. The goal was to reduce the concentrations of the drugs carbamazepine (CBZ) and venlafaxine (VLX) before discharging the wastewater to the municipal

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務